|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
Navigating the Nuances: Exploring Imaging Options and Impact on Treatment Strategies in nmCRPC
|
|
Ryan Malone, MD
|
| Zach Klaassen and Ryan Malone discuss the management of nonmetastatic castration-resistant prostate cancer, focusing on the evolving role of PSMA PET imaging. They highlight the importance of defining PSA progression and the challenges posed by new imaging techniques in identifying low-volume disease.
|
|
|
|
|
|
|
|
|
|
|
|
| PSMA-PET Implications for Extent and Survival Outcomes in High-Risk nmCRPC: An International Study |
Boris Hadaschik, MD
Alicia Morgans welcomes Boris Hadaschik to discuss the implications of using PSMA PET in non-metastatic castration-resistant prostate cancer treatment. Their focus lies on Dr. Hadaschik's presentation examining the long-term outcomes and clinical implications of this technology. |
|
|
|
|
|
|
|
|
|
|
|
Exploring the Expanding Role of Advanced Practice Providers in Urologic Oncology
|
Anne Lizardi-Calvaresi, APN, CRNP
In this engaging conversation, Sam Chang discusses the evolving role of Advanced Practice Providers in urologic oncology with Anne Lizardi-Calvaresi. Lizardi-Calvaresi shares her experiences in leading an educational course focused on systemic therapies.
|
|
|
|
|
|
|
|
|
|
|
| PSMA Ligand PET Disease Extent and Overall Survival in Patients with High-Risk nmCRPC: An International Multicenter Retrospective Study
|
| Boris Hadaschik, MD
|
| Boris Hadaschik presents findings from an international retrospective study, evaluating PSMA-PET/CT in high-risk, non-metastatic castration-resistant prostate cancer. The study revealed that the presence of ≥5 PSMA-detected distant lesions and higher PSMA avidity were associated with worse overall survival. These results suggest that PSMA-PET/CT findings could serve as prognostic markers in this patient population guiding treatment decisions.
|
|
|
|
|
|
| Discussant: Looking for Prostate Cancer: Will Novel Imaging Light the Way? |
| Louise Emmett, MBChB, FRACP |
| Louise Emmett discusses novel imaging modalities for advanced prostate cancer, focusing on three abstracts. The first discussed the comparison between bone scans and PSMA-PET in staging prostate cancer. The second examined PSMA-PET-guided salvage radiotherapy post-prostatectomy. Lastly, PSMA-PET findings in high-risk nmCRPC correlated with worse overall survival, suggesting PSMA-PET's potential as a prognostic marker. Dr. Emmett highlighted PSMA-PET's emerging role and emphasized the need for its integration into clinical trials across prostate cancer stages. |
|
|
|
|
|
|
|
|
|
|
| The Path Forward for Telehealth in Medicare |
| Ruchika Talwar, MD |
| The COVID-19 pandemic accelerated the adoption of telehealth services, prompting Medicare to expand coverage despite prior hesitations. MedPAC's report in June 2023 highlighted overall satisfaction among patients and providers, while also addressing concerns about quality and cost-effectiveness. With telehealth spending peaking during the pandemic, MedPAC suggests integrating telehealth into broader payment models to ensure appropriate reimbursement while acknowledging the need for further data collection and evaluation. |
|
|
|
|
|
| Not Just Phoning It In: Why Telehealth Is Vital in a Modern World
|
| Lisa Finkelstein, DO, and Kara Watts, MD
|
| Lisa Finkelstein and Kara Watts discuss the importance of telehealth services, emphasizing the need for legislative action to maintain telehealth accessibility. They outline five key priorities, including eliminating the originating site requirement, advocating for payment parity, supporting audio-only visits, enabling virtual supervision of healthcare providers, and addressing interstate licensure.
|
|
|
|
|
|
| Real-World Treatment Patterns for Patients with High-Risk Biochemically Recurrent Nonmetastatic Castration-Sensitive Prostate Cancer |
| Stephen Freedland, MD |
| Stephen Freedland presents findings from a real-world analysis of treatment patterns for patients with high-risk, biochemically recurrent, non-metastatic castration-sensitive prostate cancer. Utilizing data from the Adelphi Real World retrospective survey, the study analyzed first-line treatment patterns following nmCSPC diagnosis with high-risk biochemical recurrence. |
|
|
|
|
|
| Health-Related Quality of Life Deterioration-Free Survival by PSA Decline in Darolutamide-Treated Patients with Nonmetastatic Castration-Resistant Prostate Cancer from ARAMIS
|
| Alicia K. Morgans, MD, MPH |
| Alicia Morgans presents findings from an ad-hoc analysis of the ARAMIS trial focusing on health-related quality of life deterioration-free survival by PSA decline in darolutamide-treated patients with nmCRPC. The study assessed deterioration-free survival based on PSA decline groups at week 16, showing that patients receiving darolutamide who achieved PSA90 or PSA50-90 responses had longer deterioration-free survival for urinary and bowel symptoms compared to those with PSA <50 responses.
|
|
|
|
|
|
|
